{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:38:46Z","timestamp":1778539126738,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00120-021-01702-6","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T13:02:57Z","timestamp":1636117377000},"page":"1601-1611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Minimal-invasive Therapieoptionen zur Behandlung des benignen Prostatasyndroms","Minimally invasive treatment options for the management of benign prostatic hyperplasia"],"prefix":"10.1007","volume":"60","author":[{"given":"J.","family":"Franz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Suarez-Ibarrola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. S.","family":"Schoeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gratzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Miernik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"issue":"3","key":"1702_CR1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","volume":"132","author":"SJ Berry","year":"1984","unstructured":"Berry\u00a0SJ, Coffey\u00a0DS, Walsh\u00a0PC, Ewing\u00a0LL (1984) The development of human benign prostatic hyperplasia with age. J\u00a0Urol 132(3):474\u2013479. https:\/\/doi.org\/10.1016\/S0022-5347(17)49698-4","journal-title":"J Urol"},{"issue":"3","key":"1702_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ucl.2016.04.001","volume":"43","author":"KB Egan","year":"2016","unstructured":"Egan\u00a0KB (2016) The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am 43(3):289\u2013297. https:\/\/doi.org\/10.1016\/j.ucl.2016.04.001","journal-title":"Urol Clin North Am"},{"issue":"1","key":"1702_CR3","first-page":"1","volume":"22","author":"C Vuichoud","year":"2015","unstructured":"Vuichoud\u00a0C, Loughlin\u00a0KR (2015) Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol 22(1):1\u20136","journal-title":"Can J Urol"},{"key":"1702_CR4","volume-title":"EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstructions (BPO)","author":"S Gravas","year":"2021","unstructured":"Gravas\u00a0S, Cornu\u00a0JN, Gacci\u00a0M et al (2021) EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstructions (BPO). EAU Annual Congress Milan, 2021"},{"issue":"4","key":"1702_CR5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.juro.2006.11.062","volume":"177","author":"C Gratzke","year":"2007","unstructured":"Gratzke\u00a0C, Schlenker\u00a0B, Seitz\u00a0M et\u00a0al (2007) Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a\u00a0prospective multicenter study. J\u00a0Urol 177(4):1419\u20131422. https:\/\/doi.org\/10.1016\/j.juro.2006.11.062","journal-title":"J Urol"},{"issue":"1","key":"1702_CR6","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.juro.2008.03.058","volume":"180","author":"O Reich","year":"2008","unstructured":"Reich\u00a0O, Gratzke\u00a0C, Bachmann\u00a0A et\u00a0al (2008) Morbidity, mortality and early outcome of transurethral resection of the prostate: a\u00a0 prospective multicenter evaluation of 10,654\u00a0patients. J\u00a0Urol 180(1):246\u2013249. https:\/\/doi.org\/10.1016\/j.juro.2008.03.058","journal-title":"J Urol"},{"issue":"4","key":"1702_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41391-019-0135-4","volume":"22","author":"Y Zhang","year":"2019","unstructured":"Zhang\u00a0Y, Yuan\u00a0P, Ma\u00a0D et al (2019) Efficacy and safety of enucleation vs. resection of prostate for treatment of benign prostatic hyperplasia: a\u00a0meta-analysis of randomized controlled trials. Prostate Cancer Prostatic Dis 22(4):493\u2013508. https:\/\/doi.org\/10.1038\/s41391-019-0135-4","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"1702_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/iju.12866","volume":"23","author":"G Marra","year":"2016","unstructured":"Marra\u00a0G, Sturch\u00a0P, Oderda\u00a0M, Tabatabaei\u00a0S, Muir\u00a0G, Gontero\u00a0P (2016) Systematic review of lower urinary tract symptoms\/benign prostatic hyperplasia surgical treatments on men\u2019s ejaculatory function: time for a\u00a0bespoke approach? Int J Urol 23(1):22\u201335. https:\/\/doi.org\/10.1111\/iju.12866","journal-title":"Int J Urol"},{"key":"1702_CR9","volume-title":"EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO)","author":"S Gravas","year":"2018","unstructured":"Gravas\u00a0S, Cornu\u00a0JN, Drake\u00a0M et al (2018) EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO)"},{"key":"1702_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/RRU.S55340","volume":"7","author":"F Aoun","year":"2015","unstructured":"Aoun\u00a0F, Marcelis\u00a0Q, Roumegu\u00e8re\u00a0T (2015) Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology update. Res Rep Urol 7:125\u2013136. https:\/\/doi.org\/10.2147\/RRU.S55340","journal-title":"Res Rep Urol"},{"key":"1702_CR11","volume-title":"EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO)","author":"S Gravas","year":"2019","unstructured":"Gravas\u00a0S, Cornu\u00a0J, Gacci\u00a0M et al (2019) EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO)"},{"issue":"5","key":"1702_CR12","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.juro.2007.01.005","volume":"177","author":"JN Armitage","year":"2007","unstructured":"Armitage\u00a0JN, Cathcart\u00a0PJ, Rashidian\u00a0A, De Nigris\u00a0E, Emberton\u00a0M, van der Meulen\u00a0JHP (2007) Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature. J\u00a0Urol 177(5):1619\u20131624. https:\/\/doi.org\/10.1016\/j.juro.2007.01.005","journal-title":"J Urol"},{"issue":"6","key":"1702_CR13","first-page":"8590","volume":"23","author":"C MacRae","year":"2016","unstructured":"MacRae\u00a0C, Gilling\u00a0P (2016) How I do it: aquablation of the prostate using the aquabeam system. Can J Urol 23(6):8590\u20138593","journal-title":"Can J Urol"},{"key":"1702_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/S00345-020-03426-2","author":"G M\u00fcllhaupt","year":"2021","unstructured":"M\u00fcllhaupt\u00a0G, Enzler-Tschudy\u00a0A, Horg\u00a0K et al (2021) Informative value of histological assessment of tissue acquired during aquablation of the prostate. World J Urol. https:\/\/doi.org\/10.1007\/S00345-020-03426-2","journal-title":"World J Urol"},{"issue":"1","key":"1702_CR15","first-page":"10072","volume":"27","author":"P Gilling","year":"2020","unstructured":"Gilling\u00a0P, Barber\u00a0N, Bidair\u00a0M et al (2020) Three-year outcomes after aquablation therapy compared to TURP: results from a\u00a0blinded randomized trial. Can J Urol 27(1):10072\u201310079","journal-title":"Can J Urol"},{"key":"1702_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/S00345-021-03660-2","author":"AJ Gross","year":"2021","unstructured":"Gross\u00a0AJ, Lipp\u00a0MJ, Baumbach\u00a0R et\u00a0al (2021) Rectal perforation after aquablation of the prostate: lessons learned the hard way. World J Urol. https:\/\/doi.org\/10.1007\/S00345-021-03660-2","journal-title":"World J Urol"},{"issue":"2","key":"1702_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/BJU.14703","volume":"124","author":"M Desai","year":"2019","unstructured":"Desai\u00a0M, Bidair\u00a0M, Zorn\u00a0KC et al (2019) Aquablation for benign prostatic hyperplasia in large prostates (80\u2013150\u202fmL): 6\u2011month results from the WATER II trial. BJU Int 124(2):321\u2013328. https:\/\/doi.org\/10.1111\/BJU.14703","journal-title":"BJU Int"},{"issue":"2","key":"1702_CR18","first-page":"10147","volume":"27","author":"M Desai","year":"2020","unstructured":"Desai\u00a0M, Bidair\u00a0M, Bhojani\u00a0N et al (2020) Aquablation for benign prostatic hyperplasia in large prostates (80\u2013150 cc): 2\u2011year results. Can J Urol 27(2):10147\u201310153","journal-title":"Can J Urol"},{"key":"1702_CR19","doi-asserted-by":"publisher","first-page":"k2338","DOI":"10.1136\/bmj.k2338","volume":"361","author":"D Abt","year":"2018","unstructured":"Abt\u00a0D, Hechelhammer\u00a0L, M\u00fcllhaupt\u00a0G et al (2018) Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ 361:k2338. https:\/\/doi.org\/10.1136\/bmj.k2338","journal-title":"BMJ"},{"issue":"2","key":"1702_CR20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1148\/radiol.2019181524","volume":"291","author":"JL Zhang","year":"2019","unstructured":"Zhang\u00a0JL, Wang\u00a0MQ, Shen\u00a0YG et al (2019) Effectiveness of contrast-enhanced MR angiography for visualization of the prostatic artery prior to prostatic arterial embolization. Radiology 291(2):370\u2013378. https:\/\/doi.org\/10.1148\/radiol.2019181524","journal-title":"Radiology"},{"issue":"6","key":"1702_CR21","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.euf.2018.09.005","volume":"5","author":"V Zumstein","year":"2019","unstructured":"Zumstein\u00a0V, Betschart\u00a0P, Vetterlein\u00a0MW et al (2019) Prostatic artery embolization versus standard surgical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol Focus 5(6):1091\u20131100. https:\/\/doi.org\/10.1016\/j.euf.2018.09.005","journal-title":"Eur Urol Focus"},{"issue":"1","key":"1702_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/J.EURURO.2021.02.008","volume":"80","author":"D Abt","year":"2021","unstructured":"Abt\u00a0D, M\u00fcllhaupt\u00a0G, Hechelhammer\u00a0L et al (2021) Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2\u2011yr outcomes of a\u00a0randomised, open-label, single-centre trial. Eur Urol 80(1):34\u201342. https:\/\/doi.org\/10.1016\/J.EURURO.2021.02.008","journal-title":"Eur Urol"},{"issue":"2","key":"1702_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.juro.2016.08.100","volume":"197","author":"SR Shim","year":"2017","unstructured":"Shim\u00a0SR, Kanhai\u00a0KJK, Ko\u00a0YM, Kim\u00a0JH (2017) Efficacy and safety of prostatic arterial embolization: systematic review with meta-analysis and meta-regression. J\u00a0Urol 197(2):465\u2013479. https:\/\/doi.org\/10.1016\/j.juro.2016.08.100","journal-title":"J Urol"},{"key":"1702_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-019-0440-1","author":"YL Jiang","year":"2019","unstructured":"Jiang\u00a0YL, Qian\u00a0LJ (2019) Transurethral resection of the prostate versus prostatic artery embolization in the treatment of benign prostatic hyperplasia: a meta-analysis. BMC Urol. https:\/\/doi.org\/10.1186\/s12894-019-0440-1","journal-title":"BMC Urol"},{"issue":"7","key":"1702_CR25","doi-asserted-by":"publisher","first-page":"E347","DOI":"10.5489\/CUAJ.6239","volume":"14","author":"F Couture","year":"2020","unstructured":"Couture\u00a0F, Belzile\u00a0F, No\u00ebl-Lamy\u00a0M, Ponsot\u00a0Y, Tu\u00a0LM (2020) Images\u2014penile necrotic ulcer following prostatic artery embolization: a rare complication. Can Urol Assoc\u00a0J 14(7):E347. https:\/\/doi.org\/10.5489\/CUAJ.6239","journal-title":"Can Urol Assoc J"},{"issue":"10","key":"1702_CR26","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/S00270-017-1765-3","volume":"40","author":"AM Moreira","year":"2017","unstructured":"Moreira\u00a0AM, de Assis\u00a0AM, Carnevale\u00a0FC, Antunes\u00a0AA, Srougi\u00a0M, Cerri\u00a0GG (2017) A review of adverse events related to prostatic artery embolization for treatment of bladder outlet obstruction due to BPH. Cardiovasc Intervent Radiol 40(10):1490\u20131500. https:\/\/doi.org\/10.1007\/S00270-017-1765-3","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"1702_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jsxm.2016.03.372","volume":"13","author":"KT McVary","year":"2016","unstructured":"McVary\u00a0KT, Gange\u00a0SN, Gittelman\u00a0MC et\u00a0al (2016) Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study. J\u00a0Sex Med 13(6):924\u2013933. https:\/\/doi.org\/10.1016\/j.jsxm.2016.03.372","journal-title":"J Sex Med"},{"key":"1702_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2018.12.041","volume":"126","author":"KT McVary","year":"2019","unstructured":"McVary\u00a0KT, Rogers\u00a0T, Roehrborn\u00a0CG (2019) Rez\u016bm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4\u2011year results from randomized controlled study. Urology 126:171\u2013179. https:\/\/doi.org\/10.1016\/j.urology.2018.12.041","journal-title":"Urology"},{"key":"1702_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.urology.2019.06.027","volume":"132","author":"KA Parikh","year":"2019","unstructured":"Parikh\u00a0KA, Dora\u00a0CD (2019) Holmium laser enucleation of the prostate after failed urolift: surgical considerations for the management of nonabsorbable implants. Urology 132:212. https:\/\/doi.org\/10.1016\/j.urology.2019.06.027","journal-title":"Urology"},{"issue":"4","key":"1702_CR30","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.eururo.2014.10.031","volume":"67","author":"M Perera","year":"2015","unstructured":"Perera\u00a0M, Roberts\u00a0MJ, Doi\u00a0SAR, Bolton\u00a0D (2015) Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol 67(4):704\u2013713. https:\/\/doi.org\/10.1016\/j.eururo.2014.10.031","journal-title":"Eur Urol"},{"issue":"2","key":"1702_CR31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1743-6109.2011.02568.x","volume":"9","author":"HH Woo","year":"2012","unstructured":"Woo\u00a0HH, Bolton\u00a0DM, Laborde\u00a0E et\u00a0al (2012) Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J\u00a0Sex Med 9(2):568\u2013575. https:\/\/doi.org\/10.1111\/j.1743-6109.2011.02568.x","journal-title":"J Sex Med"},{"issue":"1","key":"1702_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1464-410X.2011.10342.x","volume":"108","author":"HH Woo","year":"2011","unstructured":"Woo\u00a0HH, Chin\u00a0PT, McNicholas\u00a0TA et\u00a0al (2011) Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 108(1):82\u201388. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10342.x","journal-title":"BJU Int"},{"issue":"6","key":"1702_CR33","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.juro.2013.05.116","volume":"190","author":"CG Roehrborn","year":"2013","unstructured":"Roehrborn\u00a0CG, Gange\u00a0SN, Shore\u00a0ND et\u00a0al (2013) The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. study. J\u00a0Urol 190(6):2161\u20132167. https:\/\/doi.org\/10.1016\/j.juro.2013.05.116","journal-title":"J Urol"},{"issue":"2","key":"1702_CR34","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.eururo.2013.01.008","volume":"64","author":"TA McNicholas","year":"2013","unstructured":"McNicholas\u00a0TA, Woo\u00a0HH, Chin\u00a0PT et\u00a0al (2013) Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol 64(2):292\u2013299. https:\/\/doi.org\/10.1016\/j.eururo.2013.01.008","journal-title":"Eur Urol"},{"issue":"1","key":"1702_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.urology.2011.10.021","volume":"79","author":"PT Chin","year":"2012","unstructured":"Chin\u00a0PT, Bolton\u00a0DM, Jack\u00a0G et al (2012) Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 79(1):5\u201311. https:\/\/doi.org\/10.1016\/j.urology.2011.10.021","journal-title":"Urology"},{"issue":"3","key":"1702_CR36","first-page":"8802","volume":"24","author":"CG Roehrborn","year":"2017","unstructured":"Roehrborn\u00a0CG, Barkin\u00a0J, Gange\u00a0SN et\u00a0al (2017) Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 24(3):8802\u20138813","journal-title":"Can J Urol"},{"issue":"5","key":"1702_CR37","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bju.13714","volume":"119","author":"C Gratzke","year":"2017","unstructured":"Gratzke\u00a0C, Barber\u00a0N, Speakman\u00a0MJ et al (2017) Prostatic urethral lift vs transurethral resection of the prostate: 2\u2011year results of the BPH6 prospective, multicentre, randomized study. BJU Int 119(5):767\u2013775. https:\/\/doi.org\/10.1111\/bju.13714","journal-title":"BJU Int"},{"issue":"3","key":"1702_CR38","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41391-018-0118-x","volume":"22","author":"D Rukstalis","year":"2019","unstructured":"Rukstalis\u00a0D, Grier\u00a0D, Stroup\u00a0SP et\u00a0al (2019) Prostatic urethral lift (PUL) for obstructive median lobes: 12\u00a0month results of the MedLift study. Prostate Cancer Prostatic Dis 22(3):411\u2013419. https:\/\/doi.org\/10.1038\/s41391-018-0118-x","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"1702_CR39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/bju.14141","volume":"122","author":"F Porpiglia","year":"2018","unstructured":"Porpiglia\u00a0F, Fiori\u00a0C, Bertolo\u00a0R et al (2018) 3\u2011Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. BJU Int 122(1):106\u2013112. https:\/\/doi.org\/10.1111\/bju.14141","journal-title":"BJU Int"},{"issue":"12","key":"1702_CR40","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1007\/s00345-020-03140-z","volume":"38","author":"G Kadner","year":"2020","unstructured":"Kadner\u00a0G, Valerio\u00a0M, Giannakis\u00a0I et al (2020) Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2\u00a0year results of the MT-02-study. World J Urol 38(12):3235\u20133244. https:\/\/doi.org\/10.1007\/s00345-020-03140-z","journal-title":"World J Urol"},{"issue":"8","key":"1702_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11934-019-0912-6","volume":"20","author":"D Amparore","year":"2019","unstructured":"Amparore\u00a0D, De Cillis\u00a0S, Volpi\u00a0G et al (2019) First- and second-generation temporary Implantable nitinol devices as minimally invasive treatments for BPH-related LUTS: systematic review of the literature. Curr Urol Rep 20(8):47. https:\/\/doi.org\/10.1007\/s11934-019-0912-6","journal-title":"Curr Urol Rep"},{"issue":"6","key":"1702_CR42","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/bju.14608","volume":"123","author":"F Porpiglia","year":"2019","unstructured":"Porpiglia\u00a0F, Fiori\u00a0C, Amparore\u00a0D et al (2019) Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a\u00a0prospective, multicentre study at 1\u00a0year of follow-up. BJU Int 123(6):1061\u20131069. https:\/\/doi.org\/10.1111\/bju.14608","journal-title":"BJU Int"},{"issue":"8","key":"1702_CR43","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nrurol.2015.169","volume":"12","author":"G Magistro","year":"2015","unstructured":"Magistro\u00a0G, Stief\u00a0CG, Gratzke\u00a0C (2015) New intraprostatic injectables and prostatic urethral lift for male LUTS. Nat Rev Urol 12(8):461\u2013471. https:\/\/doi.org\/10.1038\/nrurol.2015.169","journal-title":"Nat Rev Urol"},{"issue":"1","key":"1702_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11255-015-1153-3","volume":"48","author":"SR Shim","year":"2016","unstructured":"Shim\u00a0SR, Cho\u00a0YJ, Shin\u00a0IS, Kim\u00a0JH (2016) Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a\u00a0systematic review and meta-analysis. Int Urol Nephrol 48(1):19\u201330. https:\/\/doi.org\/10.1007\/s11255-015-1153-3","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"1702_CR45","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.juro.2012.11.003","volume":"189","author":"MM Elhilali","year":"2013","unstructured":"Elhilali\u00a0MM, Pommerville\u00a0P, Yocum\u00a0RC, Merchant\u00a0R, Roehrborn\u00a0CG, Denmeade\u00a0SR (2013) Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. J\u00a0Urol 189(4):1421\u20131426. https:\/\/doi.org\/10.1016\/j.juro.2012.11.003","journal-title":"J Urol"},{"issue":"5","key":"1702_CR46","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.eururo.2010.11.024","volume":"59","author":"SR Denmeade","year":"2011","unstructured":"Denmeade\u00a0SR, Egerdie\u00a0B, Steinhoff\u00a0G, Merchant\u00a0R, Abi-Habib\u00a0R, Pommerville\u00a0P (2011) Phase 1 and 2\u00a0studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 59(5):747\u2013754. https:\/\/doi.org\/10.1016\/j.eururo.2010.11.024","journal-title":"Eur Urol"},{"issue":"5","key":"1702_CR47","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00345-018-2185-y","volume":"36","author":"N Shore","year":"2018","unstructured":"Shore\u00a0N, Tutrone\u00a0R, Efros\u00a0M et al (2018) Fexapotide triflutate: results of long-term safety and efficacy trials of a\u00a0novel injectable therapy for symptomatic prostate enlargement. World J Urol 36(5):801\u2013809. https:\/\/doi.org\/10.1007\/s00345-018-2185-y","journal-title":"World J Urol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01702-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-021-01702-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01702-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T14:04:53Z","timestamp":1638972293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-021-01702-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1702"],"URL":"https:\/\/doi.org\/10.1007\/s00120-021-01702-6","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"assertion":[{"value":"12 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>J.\u00a0Franz<\/b>: A.\u00a0Finanzielle Interessen: J.K.\u00a0Franz gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Wissenschaftliche Hilfskraft der Sektion Urotechnologie, Klinik f\u00fcr Urologie, Department Chirurgie, Universit\u00e4tsklinikum Freiburg. <b>R.\u00a0Suarez-Ibarrola<\/b>: A.\u00a0Finanzielle Interessen: R.\u00a0Suarez-Ibarrola gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenzarzt, Klinik f\u00fcr Urologie, Universit\u00e4tsklinikum Freiburg | Mitgliedschaft: European Association of Urology. <b>D. S.\u00a0Schoeb<\/b>: A.\u00a0Finanzielle Interessen: D.\u00a0Schoeb gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Urologe, Facharzt, Klinik f\u00fcr Urologie, Uniklinikum Freiburg | Mitgliedschaften: DGU, EAU, GESRU, Marburger Bund. <b>C.\u00a0Gratzke<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Astellas Pharma, Neotract, Medi-Tate, Recordati.\u00a0\u2013 Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Astellas, Olympus, Recordati, Procept, Medi-Tate, MSD, AstraZeneca, Roche, GSK.\u00a0\u2013 Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: Astellas, Amgen, Ipsen, Janssen, Bayer, Takeda, Medac.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: \u00c4rztlicher Direktor, Klinik f\u00fcr Urologie, Universit\u00e4tsklinikum Freiburg | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Urologie, Europ\u00e4ische Gesellschaft f\u00fcr Urologie, Endourological Society, American Urological Association. <b>A.\u00a0Miernik<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Bundesministerium f\u00fcr Bildung und Forschung (BMBF, DE), Dornier MedTech Europe GmbH, DE.\u00a0\u2013 Reisesponsoring: Deutsche Gesellschaft f\u00fcr Urologie, Europ\u00e4ische Gesellschaft f\u00fcr Urologie (NL), Procept Biorobotics (USA).\u00a0\u2013 Autor: Verlag Walter de Gruyter, Springer Verlag, Berater: KLS Martin, Tuttlingen (Berater\u00a0A), Dornier MedTech Europe GmbH, B. Braun New Ventures GmbH, Medi-Tate Ltd. (Israel), Reviewer: Ludwig Boltzmann Gesellschaft,\u00a0A, Referent: Richard Wolf GmbH.\u00a0\u2013 Patent: Purenum GmbH, Deutschland.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Gesch\u00e4ftsf\u00fchrender Oberarzt, Personaloberarzt, Department Chirurgie, Klinik f\u00fcr Urologie, Sektion f\u00fcr Urotechnologie, Universit\u00e4tsklinikum Freiburg | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Urologie, Europ\u00e4ische Gesellschaft f\u00fcr Urologie, Endourological Society, Americal Urological Association, Deutsche Gesellschaft f\u00fcr Extrakorporale Sto\u00dfwellentherapie.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}